Baytacare Pharmaceutical Co., Ltd. provided loss guidance for the year ended December 31, 2018. The Company informed the shareholders of the Company and potential investors that, based on the preliminary review of the management accounts of the Group for the year ended 31 December 2018, the Group is expected to record an increase in net loss for the year ended 31 December 2018 as compared with the net loss for the same period of the previous year.